Departments & Divisions
Institutes & Centers
A. Enrique Diaz, MD, MSc
Associate Professor / Clinical
Dr. Diaz is a Faculty member in the Division of Hematology-Oncology. He completed his medical training with honors at the Pontificia Universidad Javeriana (Colombia) and his Internal Medicine residency at New York University. He completed his Fellowship in Hematology-Oncology and also received a Master of Science in Clinical Investigation and Translational Science degree, both from University of Texas Health Science Center San Antonio. His research and clinical interests focus on improving outcomes in patients with lymphomas and also on health care disparities. Currently, he is the Leader of the Adult Lymphoma Program at Mays Cancer Center, and serves as Ambassador and Member of the Committee on Promoting Diversity for the American Society of Hematology.
- 2017 - Clinical Fellowship - UT Health San Antonio/Mays Cancer Center/MD Anderson
- 2017 - MS - UT Health San Antonio
- 2011 - Residency - New York University (NYU)/Woodhull Medical Center
- 2009 - Internship - New York University (NYU)/Woodhull Medical Center
- 2001 - MD - Medical School - Pontificia Universidad Javeriana
- 11/2017 - Associate Professor/Clinical - UT Health San Antonio/Mays Cancer Center/MD AndersonSan Antonio
- Population-Based Analysis of Hispanic Vs Non-Hispanic Patients Diagnosed with Hodgkin Lymphoma in Texas and Florida
- Ethnicity, Nativity and Outcomes in Burkitt Lymphoma Among US Hispanics: Texas and Florida State Database Study
- Ethnicity Matters When Comparing Overall Survival for Patients Diagnosed with Follicular Lymphoma
- Insurance Is No Longer a Determinant to Improve Overall Survival for Patients Diagnosed with HL, DLBCL or PCNS in an Enriched Hi
- Primary Central Nervous System Lymphoma: A Retrospective Study of the Population of Texas and Florida with an Emphasis on Surviv
- Disparities in Mantle Cell Lymphoma Outcomes in Hispanics: A Population Based Analysis in Texas and Florida
- A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in
- Demographic Differences in the Treatment and Mortality of Lymphoplasmacytic Lymphoma in Texas: Does Ethnicity Play Any Role?
- Is There a Disparity in Oncological Outcomes for Hispanics? Analysis of Burkitt Lymphoma
- Population Based Analysis of Mantle Cell Lymphoma in Texas: Are Outcomes Any Different in Hispanics?
- Survival and Outcomes for T-Cell Lymphomas in a Ubiquitous Hispanic Community: A Texas Cancer Registry Retrospective Study
- Does Hispanic Origin Affect the Repartition and Outcome of Marginal Zone Lymphoma?
- A First Large Statewide Population Based Study Evaluating Racial Differences in Treatment and Survival between Hispanics and Non
- Ethnic Disparities in Hodgkin's Lymphoma (HL): A Large-Scale Population Based Analysis of Hispanics with HL in Texas
- Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients
- Diffuse Large B Cell Lymphoma (DLBCL) Experience in a Majority-Minority Community: The UT Health San Antonio Story
- Hodgkin Lymphoma Outcomes: Can We Expect Ethnic Parity in a Hispanic Prevalent Population?
- Does Insurance Status Interfere with Outcomes in Patients with Hodgkin and Non-Hodgkin Lymphoma?: The UT Health San Antonio Expe
- Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP as First-Line Therapy for High-Risk Diffuse Large B C
- Payment Plans Bridging Gap: An Equalizer for the Hispanic Population with Lymphoid Neoplasms in a Majority-Minority Community
- Treatment Evolution for Multiple Myeloma before Autologous Stem Cell Transplant and Its Relation with Engraftment Syndrome: 15 Y
- A Phase 2, Investigator Initiated Study to Determine the Safety, Efficacy and CNS Penetration of TVB-2640 in Recurrent High Grad
- Concurrent Acute Kidney Injury with Vancomycin Use during the Engraftment Period in Patients Undergoing Autologous Stem Cell Tra
- A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML
- Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single Institu
- American Board of Internal Medicine/Hematology
- American Board of Internal Medicine
- American Board of Internal Medicine/Medical Oncology